For HER2-positive advanced gastric cancer, discoveries of the ToGA trial found that chemotherapy regimen consisting of capecitabine plus or fluorouracil plus cisplatin in combination with trastuzumab was a promising option for patients with HER2-positive advanced gastric cancer (11). Here, ERBB2 is linked to gastric cancer.